Parties have settled a lawsuit over claims that the antipsychotic drug Risperdal caused a young man to grow excessive breast tissue that had been set to start trial Monday.
The case N.F. v. Janssen Pharmaceuticals settled for a confidential sum last week. The case would have been the sixth to hit trial out of the Risperdal mass tort program, and the first to go before a jury since Janssen Pharmaceuticals, a Johnson & Johnson subsidiary, was hit with a $70 million verdict over similar claims in July.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
